WNK2 and breast carcinoma: Wu et al.42 demonstrated that prosaposin could upregulate estrogen receptor alpha expression through the mitogen-activated protein kinase (MAPK)-signaling pathway and suggested that prosaposin may be involved in breast cancer development and progression.